Geodon, Abilify Have Low Diabetes Risk, ADA Says; Lilly Disagrees
• By The Pink Sheet
An American Diabetes Association "consensus" statement on antipsychotics and the risk of diabetes may help Pfizer and Bristol-Myers Squibb make the case to FDA to exempt Geodon and Abilify from class labeling
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
